Bjørn Tore
Gjertsen
Professor
Visit Address:
Haukeland universitetssykehus, Laboratoriebygget
5021 Bergen
Postal Address:
Postboks 7804
5021 Bergen
Phone:
+47 55 97 29 68
+47 415 66 248
E-mail:
Journal articles
- 2014. Deficient phosphorylation of stat-1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta. PLoS ONE. 9. doi: 10.1371/journal.pone.0088632
- 2014. Mot en mer spesifikk kreftbehandling? :. Tidsskrift for Den norske legeforening. 134: 1017. doi: 10.4045/tidsskr.14.0574
- 2014. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Molecular Cancer. 13. doi: 10.1186/1476-4598-13-116
- 2014. First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. PLoS ONE. 9. doi: 10.1371/journal.pone.0089527
- 2014. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft. Molecular Imaging and Biology. 16: 53-62. doi: 10.1007/s11307-013-0672-5
- 2014. Sonoporation: from the lab to human clinical trials. IEEE International Ultrasonics Symposium Proceedings. 4 pages.
- 2014. Evaluation of the effects of clinical diagnostic ultrasound in combination with ultrasound contrast agents on cell stress: single cell analysis of intracellular phospho-signaling pathways in blood cancer cells and normal blood leukocytes. IEEE International Ultrasonics Symposium Proceedings. 5 pages.
- 2014. A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. Leukemia and Lymphoma. 55: 2114-2119. doi: 10.3109/10428194.2013.867489
- 2013. Tunneling nanotube (TNT) formation is independent of p53 expression. Cell Death and Differentiation. 20: 1124-1124. doi: 10.1038/cdd.2013.61
- 2013. Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine. BMC Pharmacology & Toxicolog. 14. 13 pages. doi: 10.1186/2050-6511-14-35
- 2013. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clinical Epigenetics. 5:13. doi: 10.1186/1868-7083-5-13
- 2013. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clinical Epigenetics. 5:12. doi: 10.1186/1868-7083-5-12
- 2013. Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death & Disease. 4. doi: 10.1038/cddis.2013.39
- 2013. PANOBINOSTAT / CARBOPLATIN DELAY POSTSURGICAL RELAPSE OF OVARIAN CARCINOMA IN AN ORTHOTOPIC MOUSE MODEL. International Journal of Gynecological Cancer. 23. 1 pages.
- 2013. Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen. BMC Cancer. 13. doi: 10.1186/1471-2407-13-341
- 2013. cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases. International Journal of Oncology. 42: 1815-1821. doi: 10.3892/ijo.2013.1853
- 2013. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1-and LAGE-1-positive tumors. Cancer Immunology and Immunotherapy. 62: 773-785. doi: 10.1007/s00262-012-1384-4
- 2013. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. 121: E34-E42. doi: 10.1182/blood-2012-05-429555
- 2013. Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. Cancer Research. 74: 1276-1286. doi: 10.1158/0008-5472.CAN-12-2649
- 2013. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia. 27: 1520-1526. doi: 10.1038/leu.2013.19
- 2013. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discovery. 3: 1416-1429. doi: 10.1158/2159-8290.CD-13-0350
- 2013. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions? Current Cancer Drug Targets. 13: 30-47. doi: 10.2174/1568009611309010030
- 2013. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opinion on Investigational Drugs. 22: 551-563. doi: 10.1517/13543784.2013.791280
- 2013. Expression of TP53 isoforms p53 beta or p53 gamma enhances chemosensitivity in TP53(null) cell lines. PLoS ONE. 8. 11 pages. doi: 10.1371/journal.pone.0056276
- 2013. Gel2DE-A software tool for correlation analysis of 2D gel electrophoresis data. BMC Bioinformatics. 14. 5 pages. doi: 10.1186/1471-2105-14-215
- 2012. Humane celler og helseforskningsloven. Tidsskrift for Den norske legeforening. 132: 540-542. doi: 10.4045/tidsskr.11.1076
- 2012. Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLoS ONE. 7. doi: 10.1371/journal.pone.0048992
- 2012. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. American Journal of Hematology. 87: 368-376. doi: 10.1002/ajh.23116
- 2012. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. Multiple Sclerosis. 18: 1116-1124. doi: 10.1177/1352458511434066
- 2012. Single cell pStat1 activation, a promising biomarker to evaluate neutralizing antibody effects in interferon-beta treated multiple sclerosis patients. Journal of Neuroimmunology. 253: 18-19.
- 2012. Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. European Journal of Clinical Investigation. 42: 1016-1026. doi: 10.1111/j.1365-2362.2012.02675.x
- 2012. Investigation of therapy resistance mechanisms in myeloid leukemia by protein profiling of bone marrow extracellular fluid. Espert Review of Proteomics. 9: 595-598. doi: 10.1586/EPR.12.55
- 2012. Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. Cell Death and Differentiation. 19: 1381-1389. doi: 10.1038/cdd.2012.15
- 2012. Establishment of a bioluminescence orthotopic mouse model of ovarian carcinoma: Analysis of tumor growth and response to therapy. Acta Obstetricia et Gynecologica Scandinavica. 91: 16-17.
- 2012. Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting. Journal of Proteomics. 76: 69-78. doi: 10.1016/j.jprot.2012.07.021
- 2012. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 26: 910-917. doi: 10.1038/leu.2011.315
- 2012. Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biology and Toxicology. 28: 201-212. doi: 10.1007/s10565-012-9216-z
- 2012. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. British Journal of Haematology. 156: 468-480. doi: 10.1111/j.1365-2141.2011.08960.x
- 2012. A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline. Blood. 120. 2 pages.
- 2012. Targeting of polo-like kinases and their cross talk with Aurora kinases - possible therapeutic strategies in human acute myeloid leukemia? Expert Opinion on Investigational Drugs. 21: 587-603. doi: 10.1517/13543784.2012.668525
- 2012. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 31: 1533-1545. doi: 10.1038/onc.2011.348
- 2012. Volume visualization for exploration of population trends in two-dimensional gel electrophoresis protein data. Computer-Based Medical Systems. 1-6. Published 2012-08-30. doi: 10.1109/CBMS.2012.6266326
- 2011. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncology Reports. 25: 1549-1556. doi: 10.3892/or.2011.1229
- 2011. Stratification of pediatric acute myeloid leukemia through cancer cell gene-expression profiling. Expert Review of Anticancer Therapy. 11: 355-357. doi: 10.1586/ERA.11.8
- 2011. Untangling the intracellular signalling network in cancer - a strategy for data integration in acute myeloid leukemia. Journal of Proteomics. 74: 269-281. doi: 10.1016/j.jprot.2010.11.003
- 2011. Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer Journal. 1. doi: 10.1038/bcj.2011.2
- 2011. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Clinical and Experimental Metastasis. 28: 234-235.
- 2010. Cellular stress induced by resazurin leads to autophagy and cell death via production of reactive oxygen species and mitochondrial impairment. Journal of Cellular Biochemistry. 111: 574-584. doi: 10.1002/jcb.22741
- 2010. Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 34: 77-84. doi: 10.1016/j.leukres.2009.09.005
- 2010. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunology. 11. doi: 10.1186/1471-2172-11-38
- 2010. Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia - a report of five cases. Hematology. 15: 338-343. doi: 10.1179/102453310X12647083620967
- 2010. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Science of the United States of America. 107: 1124-1129. doi: 10.1073/pnas.0909333107
- 2010. OXYGEN LEVELS INFLUENCE THE CYTOKINE RELEASE PROFILE OF AML CELLS. Experimental Hematology. 38: S119-S119.
- 2010. Hypoxia increases HIF-1 alpha expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. European Cytokine Network. 21: 154-164. doi: 10.1684/ecn.2010.0204
- 2010. Clinical proteomics of myeloid leukemia. Genomu Igaku : Genome Medicine. 2. doi: 10.1186/gm162
- 2010. Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia. Nutrition and Cancer. 62: 574-583. doi: 10.1080/01635580903532416
- 2010. Access to the spleen microenvironment through lymph shows local cytokine production, increased cell flux, and altered signaling of immune cells during lipopolysaccharide-induced acute inflammation. Journal of Immunology. 184: 4547-4556. doi: 10.4049/jimmunol.0902049
- 2010. Combined epigenetic and signal transduction therapy modulate specific signal transduction patterns in acute myeloid leukemia. Haematologica. 95: 510-510.
- 2009. Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. Molecular Cancer. 8. doi: 10.1186/1476-4598-8-101
- 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. European Journal of Pharmacology. 625: 6-22. doi: 10.1016/j.ejphar.2009.10.009
- 2009. Er høyt hemoglobinnivå farlig? Tidsskrift for Den norske legeforening. 129: 1881-1882. doi: 10.4045/tidsskr.09.0995
- 2009. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. British Journal of Haematology. 144: 53-68. doi: 10.1111/j.1365-2141.2008.07411.x
- 2009. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 144: 53-68. doi: 10.1111/j.1365-2141.2008.07411.x
- 2009. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumour model. Neoplasia. 11: 812-822.
- 2009. Early loss of mitochondrial inner transmembrane potential in khat-induced cell death of primary normal human oral cells. Toxicology. 263: 108-116. doi: 10.1016/j.tox.2009.06.024
- 2009. The protein kinase C agonist PEP005 increases NF-kB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. British Journal of Haematology. 145: 761-774. doi: 10.1111/j.1365-2141.2009.07691.x
- 2009. Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 33: 276-287. doi: 10.1016/j.leukres.2008.06.029
- 2009. Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. Critical reviews in oncogenesis. 15: 1-41.
- 2009. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 33: 779-787. doi: 10.1016/j.leukres.2008.10.005
- 2009. Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opinion on Investigational Drugs. 18: 433-455. doi: 10.1517/14728220902787628
- 2009. TARGETING THE TUMOR STROMA: A NOVEL THERAPEUTIC STRATEGY BASED ON SEPARATE ANALYSIS OF THE MALIGNANT AND STROMAL CELL COMPARTMENTS IN BRAIN TUMORS. Neuro-Oncology. 11: 965-965.
- 2009. Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer. 9. doi: 10.1186/1471-2407-9-77
- 2008. Anticancer Immunotherapy in Combination with Proapoptotic Therapy. Current Cancer Drug Targets. 8: 666-675. doi: 10.2174/156800908786733496
- 2008. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood. 111: 2866-2877. doi: 10.1182/blood-2007-07-103242
- 2008. Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. Journal of Neuroimmunology. 203: 134-135.
- 2008. Erythropoietin a safe bet in haemorrhagic shock? Acta Anaesthesiologica Scandinavica. 52: 585-586. doi: 10.1111/j.1399-6576.2008.01651.x
- 2008. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia. 22: 287-293. doi: 10.1038/sj.leu.2404985
- 2008. Effects of benzene on human hematopoiesis. The Open Hematology Journal. 2: 87-102. doi: 10.2174/1874276900802010087
- 2008. Khat induces G1-phase arrest and increased expression of stress-sensitive p53 and p16 proteins in normal human oral keratinocytes and fibroblasts. European Journal of Oral Sciences. 116: 23-30. doi: 10.1111/j.1600-0722.2007.00508.x
- 2008. Review: genetic models of acute myeloid leukaemia. Oncogene. 27: 3765-3779. doi: 10.1038/onc.2008.16
- 2008. Evaluation of combinational therapy of MDM2-antagonist nutlin-3 and HDAC-inhibitor valproic acid in acute myeloid leukemia in vitro and in vivo. Blood. 112: 1024-1024.
- 2008. In vivo biological effects of ATRA in the treatment of AML. Expert Opinion on Investigational Drugs. 17: 1623-1633. doi: 10.1517/13543780802440136
- 2008. FLT3 internal tandem duplication involving its libiquitin dependent endocytosis motif suspend modulation by HDM2 and are associated with inferior survival in AML. Haematologica. 93: 10-10.
- 2007. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 92: 332-341.
- 2007. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. Current Pharmaceutical Biotechnology. 8: 388-400. doi: 10.2174/138920107783018417
- 2007. Synergistic anti-leukemic effect of protein kinase a activator and PPAR7agonist is independent of Bcl-2 status. Blood. 110: 117B-117B.
- 2007. T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005. Cancer Immunology and Immunotherapy. 56: 013-925. doi: 10.1007/s00262-006-0236-5
- 2007. Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. Hematology. 12: 199-207. doi: 10.1080/10245330701255163
- 2007. Effects of interferon gamma on native human acute myelogenous leukaemia cells. Cancer Immunology and Immunotherapy. 56: 13-24. doi: 10.1007/s00262-006-0159-1
- 2007. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. European Journal of Haematology. 79: 210-225. doi: 10.1111/j.1600-0609.2007.00899.x
- 2007. Bcl-2 antisense in the treatment of human malignancies: A delusion in targeted therapy. Current Pharmaceutical Biotechnology. 8: 373-381. doi: 10.2174/138920107783018381
- 2007. Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. Expert opinion on therapeutic targets. 11: 1055-1069. doi: 10.1517/14728222.11.8.1055
- 2007. LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Molecular Cancer. 6. doi: 10.1186/1476-4598-6-31
- 2007. Flt3 Y591 duplication and Bc1-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood. 109: 2589-2596. doi: 10.1182/blood-2006-02-004234
- 2007. Discrimination and quantification of spectrally similar near-infrared probes by time-domain (TD) optical imaging in acute myeloid leukemia mouse models. Blood. 110: 147B-148B.
- 2007. In vivo optical Imaging of acute myeloid leukemia by green fluorescent protein: Time-domain autofluorescence decoupling, fluorophore quantification, and localization. Molecular Imaging. 6: 193-204. doi: 10.2310/7290.2007.00016
- 2007. Anti-tumor activity of immunoproteasome selective inhibitors. Blood. 110: 477A-478A.
- 2007. Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry. 366: 46-58. doi: 10.1016/j.ab.2007.03.013
- 2007. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology. 136: 814-828. doi: 10.1111/j.1365-2141.2007.06504.x
- 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukamia cells indentify patient subgroups that differ susceptibility to histone deactylase inhibitors. International Journal of Oncology. 31: 1529-1538.
- 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in the susceptibility to histone deacetylase inhibitors. Haematologica. 92: 112-112.
- 2007. Linking susceptibility to histone deactylase inhibitors and basal gene expression profiles in acute myeloid leukaemia. Experimental Hematology. 35: 77-77.
- 2007. Flt3 mutations in proximity to an ubiquitin dependent endocytosis motif suspend its Hdm2 modulation. Blood. 110: 148B-148B.
- 2007. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Molecular Cancer. 6. doi: 10.1186/1476-4598-6-33
- 2007. Early gene expression of acute myeloid leukemia in response to chemotherapy. Expert Review of Anticancer Therapy. 7: 741-751. doi: 10.1586/14737140.7.5.741
- 2007. Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in Acute Myeloid Leukemia. Current Pharmaceutical Biotechnology. 8: 344-354. doi: 10.2174/138920107783018435
- 2006. Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. BMC Bioinformatics. 7: 198. doi: 10.1186/1471-2105-7-198
- 2006. Immunotherapy in chronic lymphocytic leukemia. Cancer Immunology and Immunotherapy. 55: 185-187. doi: 10.1007/s00262-005-0031-8
- 2006. Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert opinion on therapeutic targets. 10: 51-68. doi: 10.1517/14728222.10.1.51
- 2006. Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia? Cancer Immunology and Immunotherapy. 55: 221-228. doi: 10.1007/s00262-005-0032-7
- 2006. CaM-kinasell-dependent commitment to microcystin-induced apoptosis is coupled to cell budding, but not to shrinkage or chromatin hypercondensation. Cell Death and Differentiation. 13: 1191-1202. doi: 10.1038/sj.cdd.4401798
- 2006. Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies. Current Pharmaceutical Biotechnology. 7: 185-198. doi: 10.2174/138920106777549696
- 2006. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2 : Bax ratio and low levels of heat shock protein 70 and 90. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 30: 1531-1540.
- 2006. Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). Current Pharmaceutical Biotechnology. 7: 159-170. doi: 10.2174/138920106777549759
- 2006. Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). Current Pharmaceutical Biotechnology. 7: 159-170. doi: 10.2174/138920106777549759
- 2006. Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia. Acta Oncologica. 45: 346-349. doi: 10.1080/02841860500482233
- 2006. Adaptive contrast enhancement of two-dimensional electrophoretic protein gel images facilitates visualization, orientation and alignment. Electrophoresis. 27: 4086-4095. doi: 10.1002/elps.200500925
- 2006. Proteomics of p53 in diagnostics and therapy of acute myeloid leukemia. Current Pharmaceutical Biotechnology. 7: 199-207. doi: 10.2174/138920106777549731
- 2006. Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report. Leukemia. 20: 734-736. doi: 1038/sj.leu.2404117
- 2006. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clinical Cancer Research. 12: 3985-3992. doi: 10.1158/1078-0432.CCR-05-1970
- 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. NBS-nytt. 1: 106.
- 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. International Journal of Oncology. 28: 1065-1080.
- 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy. International Journal of Molecular Medicine. 18: S65. Published 2006-10-13.
- 2005. The role of Bcl-2 in apoptosis induced by khat (Catha edulis) in acute myeloid leukemia cell lines. Blood. 106: 195b-195b.
- 2005. Antiangiogenic therapy in acute myelogenous leukemia: Targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Current Cancer Drug Targets. 5: 229-248.
- 2005. Animal models of acute myelogenous leukaemia - development, application and future perspectives. Leukemia. 19: 687-706. doi: 10.1038/sj.leu.2403670
- 2005. In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 29: 185-196. doi: 10.1016/j.leukres.2004.06.008
- 2005. Proteomics in acute myelogenous leukaemia (AML): Methodological strategies-and identification of protein targets for novel antileukaemic therapy. Current Drug Targets. 6: 631-646. doi: 10.2174/1389450054863671
- 2005. Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. Current Drug Targets. 6: 631-646. doi: 10.2174/1389450054863671
- 2005. CD34 expression in native human acute myelogenous leukemia blasts: Differences in CD34 membrane molecule expression are associated with different gene expression profiles. Cytometry. 64B: 18-27. doi: 10.1002/cyto.b.20044
- 2004. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 103: 2925-2928.
- 2004. Rituximab for pimary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 103: 2925-2928. doi: 10.1182/blood-2003-10-3597
- 2004. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica. 89: 391-402.
- 2004. Khat (Catha edulis)-induced apoptosis is inhibited by antagonists of caspase-1 and -8 in human leukaemia cells. British Journal of Cancer. 91: 1726-1726.
- 2004. Characterization of ribosomal P autoantibodies in relation to cell destruction and autoimmune disease. Scandinavian Journal of Immunology. 60: 189-198. doi: 10.1111/j.0300-9475.2004.01450.x
- 2004. Caspase-dependent, geldanamycin-enhanced cleavage of co-chaperone p23 in leukemic apoptosis. Leukemia. 18: 1989-1996.
- 2004. How should clinical data be included in experimental studies of cancer immunology? Cancer Immunology and Immunotherapy. 53: 677-680.
- 2004. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 118: 217-228.
- 2001. Vitamin E prevents apoptosis and necrosis in U-937 cells exposed to eluates from autopolymerized denture base acrylic resins. Journal of Dental Research. 80: 1291-1291.
- 2000. In vitro Culture of Human Acute Myelogenous Leukemia (AML) Cells in Serum-Free Media: Studies of Native AML Blasts and AML Cell Lines. Journal of Hematotherapy & Stem Cell Research. 9: 923-932.
- 2000. Patterns of cell death induced by eluates from denture base acrylic resins in U-937 human monoblastoid cells. European Journal of Oral Sciences. 108: 59-69.
- 1999. Altered clonogenicity and induction of apoptotic cell death in L929 cells exposed to denture base acrylic resins. Journal of Dental Research. 78: 315-315.
- 1999. Ultrarapid apoptosis inducted by phosphatase inhibitors. Cell Death Differ. Cell Death and Differentiation. 6: 1099-1108.
- 1999. Caspase I related protease inhibition retards the execution of okadaic acid and camptothecin induced apoptosis and PAI-2 selective cleavage, but not commitment to cell death in HL-60 cells. British Journal of Cancer. 79: 1685-1691.
- 1998. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology. 11: 19-24.
- 1998. A comparative study of cytopathogenic effects of four denture base acrylic resins. Journal of Dental Research. 77: 816-816.
- 1997. Fas/APO-1 (CD95)-Induced Apoptosis of Primary Hepatocytes Is Inhibited by cAMP. Biochemical and Biophysical Research Communications - BBRC. 232: 20-25.
- 1997. Gap junctions and growth control in liver regeneration and in isolated rat hepatocytes. Hepatology. 25: 847-855.
- 1996. Kreftcellens skjulte veier til apotose. KreftNytt. 4. nove.
- 1994. Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line. Journal of Cell Science, Supplement. 107: 3363-3377.
- 1994. Cleaved intracellular plasminogen activator inhibitor-2 is a marker of apoptosis present in human myeloid leukemia cells. British Journal of Cancer. 70: 834-840.
- 1993. The genetic subtypes of cAMP-dependent protein kinase - functionally different or redundant? Biochimica et Biophysica Acta. 1178: 249-258.
- 1993. Anti-apoptotic effect of heterozygously expressed mutant RI (Ala%3%3%6 ->Asp) subunit of cAMP-kinase I in a rat leukaemia cell line. Journal of Biological Chemistry. 268: 8332-8340.
- 1993. Exogenous substrate stimulate autodephosphorylation of cyclic-AMP-dependent protein kinase II. Biochemical Journal. 294: 497-503.
- 1993. Apoptosisk celledød - finnes det fornuft i fragmenteringen? NBS-nytt. 4: 6-12.
- 1993. Apoptotisk celledød. NBS-nytt. 4: 6-12.
- 1993. Microinjected catalytic subunit of cAMP-dependent protein kinase induces apoptosis in myeloid leukemic (IPC-81) cells. Exp Cell Res. 206: 157-161.
- 1991. The protein phosphatase inhibator okadaic acid induces morphological changes typical of apoptosis in mammalian cells. Experimental Cell Research. 195: 237-246.
- 1991. Programmed cell death (apoptosis) is induced rapidly and with positive cooperativity by activation of cyclic adenosine monophosphate-kinase I in a myeloid leukemia cell line. Journal of Cellular Physiology. 146: 73-80.
Reports and theses
- 1995. cAMP-dependent protein kinase: Its regulation and its role in apoptosis of a promyelocytic leukemia cell line.
Book sections
- 2013. Ultrasound-assisted treatment of an inoperable pancreatic cancer. Session 2, pages 49-52. In:
- 2013. MedViz Conference 2013. 146 pages. ISBN: 978-82-998920-1-8.
- 2013. Ultrasound and microbubble enhanced therapy of orthotopic human pancreatic cancer in mice. Session 2, pages 45-47. In:
- 2013. MedViz Conference 2013. 146 pages. ISBN: 978-82-998920-1-8.
- 2013. Ultrasound combined with microbubbles modulates signal transduction pathways in blood cells. Poster Abstracts, pages 119-120. In:
- 2013. MedViz Conference 2013. 146 pages. ISBN: 978-82-998920-1-8.
- 2012. Microbubbles and cell interactions. Session 4, pages 53-54. In:
- 2012. MedViz Conference 2012. 104 pages. ISBN: 978-82-998920-0-1.
- 2012. Flow cytometic characterization and sorting of ultrasound contrast agents. Chapter 11, pages 171-183. In:
- 2012. Micro-acoustics in marine and medical research. 198 pages. ISBN: 978-82-303-1945-1.
- 2009. Signalhemmere. Kapittel 17, pages 226-249. In:
- 2009. Medikamentell kreftbehandling. 495 pages. ISBN: 978-829923312-5.
- 2008. Comprehensive Analysis of Gene Function: RNA interference and Chemical Genomics. Kapittel 16, pages 193-205. In:
- 2008. Genomic and personalized medicine. Academic Press. 1478 pages. ISBN: 978-0-12-369420-1.
- 1997. Hudsykdommer. 2. utgave. 312-338. In:
- 1997. Legevakthåndboken. Universitetsforlaget. ISBN: 82-00-41574-0.
- 1996. Sensitive and rapid detection of B-galactosidase expression in intact cells by microinjection of fluorecent substrate. In:
- 1996. Fluorecence microscopy and fluorescent probes.
More information in national current research information system (CRIStin)